Back to Market Feed

Product Information

DABIGATRAN ETEXILATE 110 MG CP is a generic product labeled by Dr. Reddy's Laboratories Inc., priced at $0.9460 per EA under NDC 43598045360. Its NADAC has been published 75 times since Mar 19, 2025.

FDA first approved this application on Jan 28, 2025. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

DABIGATRAN ETEXILATE 110 MG CP

Dabigatran etexilate
$0.9460per EA

Strength

110 mg/1

NDC

43598045360

Classification

Generic

Dosage Form

CAPSULE

Route

ORAL

Effective Date

8/19/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA208048

FDA Approved

1/28/2025

TE Code

AB

On Market Since

2/28/2025

Pharmacological Classes

Direct Thrombin Inhibitor
Thrombin Inhibitors

Price Statistics

The NADAC for DABIGATRAN ETEXILATE 110 MG CP has been published 75 times since Mar 19, 2025, and over the history we have for it it has declined 52.2%. The table below summarizes its recorded NADAC range and movement.

Current price$0.9460 per EA
All-time high$1.9786 (Apr 16, 2025)
All-time low$0.9196 (May 20, 2026)
52-week high$1.8359
52-week low$0.9196
Median price$1.6053
Average price$1.4744
Largest weekly change-12.4% (Dec 17, 2025)
Weeks tracked75
Tracking sinceMar 19, 2025

Price History

1W

-2.8%

1M

-2.8%

3M

+2.9%

6M

-15.4%

1Y

-48.5%

3Y

N/A

5Y

N/A

All

-52.2%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Dabigatran etexilate market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Related Drugs

Same classification

DABIGATRAN ETEXILATE 150 MG CP
Generic
00378026691•Mylan Pharmaceuticals Inc.
$0.8226
per EA
DABIGATRAN ETEXILATE 150 MG CP
Generic
00904725510•Major Pharmaceuticals
$0.8226
per EA
DABIGATRAN ETEXILATE 150 MG CP
Generic
00904725568•Major Pharmaceuticals
$0.8226
per EA
DABIGATRAN ETEXILATE 150 MG CP
Generic
31722062232•Camber Pharmaceuticals Inc.
$0.8226
per EA
DABIGATRAN ETEXILATE 150 MG CP
Generic
31722062260•Camber Pharmaceuticals Inc.
$0.8226
per EA
DABIGATRAN ETEXILATE 150 MG CP
Generic
59651097560•Aurobindo Pharma Limited
$0.8226
per EA
DABIGATRAN ETEXILATE 150 MG CP
Generic
60505434806•Apotex Corp.
$0.8226
per EA
DABIGATRAN ETEXILATE 150 MG CP
Generic
62332063606•Alembic Pharmaceuticals Inc.
$0.8226
per EA
DABIGATRAN ETEXILATE 150 MG CP
Generic
62332063660•Alembic Pharmaceuticals Inc.
$0.8226
per EA
DABIGATRAN ETEXILATE 150 MG CP
Generic
67877047560•Ascend Laboratories, LLC
$0.8226
per EA

Frequently asked questions

What is the NADAC price of DABIGATRAN ETEXILATE 110 MG CP?

The current National Average Drug Acquisition Cost (NADAC) for DABIGATRAN ETEXILATE 110 MG CP, manufactured by Dr. Reddy's Laboratories Inc., is $0.9460 per EA (NDC 43598045360), effective Aug 19, 2026.

How has the price of DABIGATRAN ETEXILATE 110 MG CP changed over time?

Over the history we have for it, the NADAC for DABIGATRAN ETEXILATE 110 MG CP has declined 52.2%. It has been tracked across 75 weekly CMS publications since Mar 19, 2025.

What are the highest and lowest recorded NADAC prices for DABIGATRAN ETEXILATE 110 MG CP?

Since Mar 19, 2025, the NADAC for DABIGATRAN ETEXILATE 110 MG CP has ranged from a low of $0.9196 (May 20, 2026) to a high of $1.9786 (Apr 16, 2025), with a median of $1.6053 per EA.

Are there cheaper alternatives to DABIGATRAN ETEXILATE 110 MG CP?

No other NADAC-published product currently shares the active ingredient and strength of DABIGATRAN ETEXILATE 110 MG CP in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures DABIGATRAN ETEXILATE 110 MG CP?

DABIGATRAN ETEXILATE 110 MG CP (NDC 43598045360) is labeled by Dr. Reddy's Laboratories Inc., and CMS classifies it as a generic product.